Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06177457 · ClinicalTrials.gov registry record · Phase 1
A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT06177457 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 88 participants.
The verdict
NCT06177457, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study has four parts: Part A, Part B, Part C, and Part D. The purpose of Part A of this study is to learn about the: * safety, * tolerability, * how PF-07293893 is processed by the body when multiple doses of PF-07293893 are given to healthy participants. The purpose of Part B of this study is to understand the effect of multiple doses of PF-07393893 on the amount of midazolam when given as a single dose by mouth. The purpose of part C of this study is to understand how PF-07293893 is changed in the body and how much PF-07293893 and it's changed forms are being removed in urine and feces after a single dose given to single participants. The purpose of Part D is to understand the effect of multiple doses of PF-07293893 on the amount of glycogen (storage form of glucose) in the muscle of healthy participants. Part B, C and D will be done if the results of Part A support further study of PF-07293893. The study is seeking participants who: * are females who are not able to give birth to a child. These female participants should be between 18 to 65 years of age. * are males of 18 to 65 years of age. * have a body mass index (BMI) of 20.0 to 35.0 kilograms per squared meter. * have total body weight of more than 45 kilograms (99 pounds). For a given participant in Part A, the total study is going to last up to about 11 weeks. This includes from the time of selection till the last follow-up phone call. The participants will be selected if they are fit for the study 28 days before the first dose of the study medicines. Participants who are selected will be admitted to the study site on Day 1 for around 18 days. Following discharge, participants will return for an on-site follow-up visit 7 to 10 days after receiving the final dose of the study medicine. The follow-up contact may be via a telephone call and will happen 28 to 35 days after the final dose of study medicine is given. For a given participant in Part B, the total study is going to last up to about 1
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG PF-07293893
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2023-12-20 |
| Est. Completion | 2024-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06177457
The ClinicalTrials.gov registry entry for NCT06177457 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06177457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06177457 about?
NCT06177457 is a clinical study titled "A Study to Understand the Effect of Multiple Ascending Doses of PF-07293893 in Healthy Adult Participants". This study has four parts: Part A, Part B, Part C, and Part D. The purpose of Part A of this study is to learn about the: * safety, * tolerability, * how PF-07293893 is processed by the body when multiple doses of PF-07293893 are given to healthy participants. The purpose of Part B of this study ...
What is the current status of trial NCT06177457?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2023-12-20. Estimated completion is 2024-12-02.
What interventions are being tested in trial NCT06177457?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), PF-07293893 (DRUG).
Who is sponsoring clinical trial NCT06177457?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.